BACKGROUND: Psoriasis is a chronic, immune-mediated @entity66 associated with substantial economic, clinical, and humanistic burden. OBJECTIVE: The aim of this study was to understand the disutility of @entity1 with @entity1569 , using mean baseline EuroQoL five dimensions (EQ-5D) index scores reported in the published literature, and to compare this to @entity1 with other @entity102 . METHODS: Two systematic literature searches were conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. Searches were conducted in ten databases including Embase, MEDLINE, and the Cochrane Central Register of Controlled Trials (CENTRAL). The first search (December 2013) used search terms psoria* AND (EQ5D OR EQ OR EUROQoL). Only publications of original research, which reported baseline EQ-5D scores for mild/moderate/severe @entity1569 , were included. The second search (March 2014) used the terms (systematic review) AND (EQ5D OR EQ 5D OR EuroQoL). Titles were screened by two independent reviewers. Four independent reviewers reviewed titles and full-length papers. EQ-5D scores for @entity1569 @entity1 were qualitatively compared with scores from @entity1 with other @entity102 identified through the literature search. RESULTS: Of 133 publications on @entity1569 , 12 met the inclusion criteria. The mean EQ-5D index scores for @entity1569 (all severities) ranged from 0.52 (standard deviation: 0.39) to 0.9 (standard deviation: 0.1). Of the 48 results from the second search, six met the inclusion criteria. The reported EQ-5D lower limit for other diseases ranged from 0.20 ( @entity6 ) to 0.66 ( @entity409 ). The highest EQ-5D estimates for other diseases ranged from 0.79 ( @entity409 ) to 0.93 ( @entity5 @entity1 ). Both lower and upper EQ-5D estimates in @entity1569 @entity1 were within the range of those reported for other @entity102 . CONCLUSION: Comparative studies of morbidity are relevant in health care studies and @entity1 advocacy. This systematic review demonstrates that the ranges of disutility among @entity1569 @entity1 are within the ranges of other @entity102 ( @entity65 , @entity6 , end-stage @entity8 , @entity409 , @entity5 , and @entity227 ).

A systematic literature review to compare quality of life in XXXX with other @entity102 using EQ-5D-derived utility values.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal diseases'] @entity227 :: ('MESH:D014786', 'Disease') :: ['visual disorders'] @entity1569 :: ('MESH:D011565', 'Disease') :: ['psoriasis', 'psoriasis vulgaris'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes', 'Type 2 diabetes mellitus'] @entity66 :: ('MESH:D004194', 'Disease') :: ['dermatological disease'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity409 :: ('MESH:D008107', 'Disease') :: ['liver diseases'] @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic diseases'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular diseases']
@entity1569 :: (MESH:D011565,Disease) :: ['psoriasis']
